RxDoctor Payments Data

Lennett Lerch, APRN

Nurse Practitioner · Eagle River, AKNPI 1104425073

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 33 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by Medtronic at 40.0% of the total. Reporting peaked in 2021 at $253 and has fallen 50.5% since, to $125 in 2025.

$897in general payments, 2019–2025

Across 33 payments — averaging $27.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$359
  • GRT US Holding, Inc.$252
  • Pfizer$70
  • AbbVie$67
  • Biohaven Pharmaceutical Holding Company Ltd.$55
  • Vertex$28
  • plus $66 from 3 others

What the payments were for

  • Food & beverage$897100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$897 in reported general payments places this provider in the 85th percentile of 212 nurse practitioner providers in Alaska.

See all nurse practitioner providers in Alaska

Medicare billing

Part B allowed, 2024
$24,537
Medicare patients
152
Services billed
270

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NucyntaTapentadol Hcl21$29,909
Nucynta ErTapentadol Hcl12$22,590
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl38$3,883
Gabapentin55$913
Pregabalin45$882
Tramadol Hcl74$455
Duloxetine Hcl25$418
Ramelteon12$414
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen29$241
Methocarbamol23$210
Acetaminophen-CodeineAcetaminophen With Codeine13$202
Methadone Hcl23$191
Tizanidine Hcl27$118

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Nucynta, Nucynta Er$28$52,49933 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 212 nurse practitioner providers in Alaska.

Other nurse practitioner in Eagle River

See the full list for Alaska

Where these figures come from

Is this you, or does something look wrong? →